|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enneli D and Baglan T: The many faces of
urothelial carcinomas: An update from pathology to clinical
approach and challenges in practice. Urol Res Pract. 49:147–161.
2023. View Article : Google Scholar
|
|
3
|
Clark PE, Agarwal N, Biagioli MC,
Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel
TM, Lele SM, et al: Bladder Cancer. J Natl Compr Canc Netw.
11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemminki K: Reactions of ethyleneimine
with guanosine and deoxyguanosine. Chem Biol Interact. 48:249–260.
1984. View Article : Google Scholar
|
|
5
|
Hemminki K and Ludlum DB: Covalent
modification of DNA by antineoplastic agents. J Natl Cancer Inst.
73:1021–1028. 1984.
|
|
6
|
Maanen MJ, Smeets CJ and Beijnen JH:
Chemistry, pharmacology and pharmacokinetics of N,N',N'
-triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev.
26:257–268. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soloway MS and Ford KS: Thiotepa-induced
myelosuppression: Review of 670 bladder instillations. J Urol.
130:889–891. 1983. View Article : Google Scholar
|
|
8
|
Faraj K, Chang YH, Rose KM, Habermann EB,
Etzioni DA, Blodgett G, Castle EP, Humphreys MR and Tyson Ii MD:
Single-dose perioperative mitomycin-C versus thiotepa for low-grade
noninvasive bladder cancer. Can J Urol. 26:9922–9930. 2019.
|
|
9
|
Chou R, Selph S, Buckley DI, Fu R, Griffin
JC, Grusing S and Gore JL: Intravesical therapy for the treatment
of nonmuscle invasive bladder cancer: A systematic review and
meta-analysis. J Urol. 197:1189–1199. 2017. View Article : Google Scholar
|
|
10
|
Koch GE, Smelser WW and Chang SS: Side
effects of intravesical BCG and chemotherapy for bladder cancer:
What they are and how to manage them. Urology. 149:11–20. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Li M, Chen Z, OuYang J and Ling
Z: Efficacy of bladder intravesical chemotherapy with three drugs
for preventing non-muscle-invasive bladder cancer recurrence. J
Healthc Eng. 2021:23607172021.PubMed/NCBI
|
|
12
|
Li R, Li Y, Song J, Gao K, Chen K, Yang X,
Ding Y, Ma X, Wang Y, Li W, et al: Intravesical gemcitabine versus
mitomycin for non-muscle invasive bladder cancer: A systematic
review and meta-analysis of randomized controlled trial. BMC Urol.
20:972020. View Article : Google Scholar
|
|
13
|
Wang L, Huang S, Zhang P and Li H, Li Z,
Xue L, Wang Z, Chen Q, Fu D, Luo Q and Li H: The application of
gemcitabine and pirarubicin in patients with non-muscle invasive
bladder cancer. J Cancer Res Clin Oncol. 149:8945–8949. 2023.
View Article : Google Scholar
|
|
14
|
Kim HS and Seo HK: Immune checkpoint
inhibitors for urothelial carcinoma. Investig Clin Urol.
59:285–296. 2018. View Article : Google Scholar
|
|
15
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar
|
|
16
|
Du Z, Yin H, Zhao S, Ma Y, Sun Z, Dong B,
Zhu M, Zhu C, Peng J and Yang T: Case report: Gemcitabine
intravesical hyperthermic infusion combined with tislelizumab in
muscle invasive bladder urothelium carcinoma. Front Oncol.
12:10626552022. View Article : Google Scholar
|
|
17
|
Liu K, Zhu J, Song YX, Wang X, Zhou KC, Lu
Y and Liu XQ: Thermal intravesical chemotherapy reduce recurrence
rate for non-muscle invasive bladder cancer patients: A
meta-analysis. Front Oncol. 10:292020. View Article : Google Scholar
|
|
18
|
Ruan Q, Ding D, Wang B, He C, Ren X, Feng
Z, Pang Z, Wang J, Zhang X, Tang H, et al: A multi-institutional
retrospective study of hyperthermic plus intravesical chemotherapy
versus intravesical chemotherapy treatment alone in intermediate
and high risk nonmuscle-invasive bladder cancer. Cancer Biol Med.
18:308–317. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van der Heijden AG, Verhaegh G, Jansen CF,
Schalken JA and Witjes JA: Effect of hyperthermia on the
cytotoxicity of 4 chemotherapeutic agents currently used for the
treatment of transitional cell carcinoma of the bladder: An in
vitro study. J Urol. 173:1375–1380. 2005. View Article : Google Scholar
|
|
20
|
Han MA, Maisch P, Jung JH, Hwang JE,
Narayan V, Cleves A, Hwang EC and Dahm P: Intravesical gemcitabine
for non-muscle invasive bladder cancer. Cochrane Database Syst Rev.
6:CD0092942021.PubMed/NCBI
|
|
21
|
Kuperus JM, Busman RD, Kuipers SK,
Broekhuizen HT, Noyes SL, Brede CM, Tobert CM and Lane BR:
Comparison of side effects and tolerability between intravesical
bacillus calmette-guerin, reduced-dose BCG and gemcitabine for
non-muscle invasive bladder cancer. Urology. 156:191–198. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shelley MD, Jones G, Cleves A, Wilt TJ,
Mason MD and Kynaston HG: Intravesical gemcitabine therapy for
non-muscle invasive bladder cancer (NMIBC): A systematic review.
BJU Int. 109:496–505. 2012. View Article : Google Scholar
|
|
23
|
Massadeh S, Almohammed I, Barhoush E, Omer
M, Aldhawi N, Almalik A and Alaamery M: Development of
epirubicin-loaded biocompatible polymer PLA-PEG-PLA Nanoparticles:
Synthesis, characterization, stability, and in vitro anticancerous
assessment. Polymers (Basel). 13:12122021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cersosimo RJ and Hong WK: Epirubicin: A
review of the pharmacology, clinical activity, and adverse effects
of an adriamycin analogue. J Clin Oncol. 4:425–439. 1986.
View Article : Google Scholar
|
|
25
|
Mantso T, Goussetis G, Franco R, Botaitis
S, Pappa A and Panayiotidis M: Effects of hyperthermia as a
mitigation strategy in DNA damage-based cancer therapies. Semin
Cancer Biol. 37–38. 96–105. 2016.
|
|
26
|
Brummelhuis ISG, Wimper Y, Witjes-van Os
HGJM, Arends TJH, van der Heijden AG and Witjes JA: Long-Term
experience with radiofrequency-induced hyperthermia combined with
intravesical chemotherapy for non-muscle invasive bladder cancer.
Cancers (Basel). 13:3772021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Owusu RA, Abern MR and Inman BA:
Hyperthermia as adjunct to intravesical chemotherapy for bladder
cancer. Biomed Res Int. 2013:2623132013. View Article : Google Scholar
|
|
28
|
Wu CC, Hsu YT and Chang CL: Hyperthermic
intraperitoneal chemotherapy enhances antitumor effects on ovarian
cancer through immune-mediated cancer stem cell targeting. Int J
Hyperthermia. 38:1013–1022. 2021. View Article : Google Scholar
|
|
29
|
Qiao X, van der Zanden SY, Wander DPA,
Borràs DM, Song JY, Li X, van Duikeren S, van Gils N, Rutten A, van
Herwaarden T, et al: Uncoupling DNA damage from chromatin damage to
detoxify doxorubicin. Proc Natl Acad Sci USA. 117:15182–15192.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schooneveldt G, Bakker A, Balidemaj E,
Chopra R, Crezee J, Geijsen ED, Hartmann J, Hulshof MC, Kok HP,
Paulides MM, et al: Thermal dosimetry for bladder hyperthermia
treatment. An overview. Int J Hyperthermia. 32:417–433. 2016.
View Article : Google Scholar
|
|
31
|
Van Bree C, Beumer C, Rodermond HM,
Haveman J and Bakker PJ: Effectiveness of
2′,2′difluorodeoxycytidine (Gemcitabine) combined with hyperthermia
in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J
Hyperthermia. 15:549–556. 1999. View Article : Google Scholar
|
|
32
|
Takahashi A, Yamamoto Y, Yasunaga M, Koga
Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, et
al: NC-6300, an epirubicin-incorporating micelle, extends the
antitumor effect and reduces the cardiotoxicity of epirubicin.
Cancer Sci. 104:920–925. 2013. View Article : Google Scholar
|
|
33
|
Kageyama S, Maeda K, Kubota S, Yoshida T,
Osafune T, Arai Y, Soga H, Nishikawa Z, Sakano Y, Takimoto K, et
al: Single short retention instillation of pirarubicin prevents
intravesical recurrence of low-risk non muscle invasive bladder
cancer. In Vivo. 35:1141–1145. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng SE, Xiong S, Lin F, Qiao GL, Feng T,
Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits
multidrug-resistant osteosarcoma cell proliferation through
induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin.
33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okamura K, Ono Y, Kinukawa T, Matsuura O,
Yamada S, Ando T, Fukatsu T, Ohno Y and Ohshima S; Nagoya
University Urological Oncology Group, : Randomized study of single
early instillation of (2′R)-4′-O-tetrahydropyranyl-doxorubicin for
a single superficial bladder carcinoma. Cancer. 94:2363–2368. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sasaki N, Ikenaka Y, Aoshima K, Aoyagi T,
Kudo N, Nakamura K and Takiguchi M: Safety Assessment of
Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A
Pilot Study. Front Pharmacol. 13:8377542022. View Article : Google Scholar
|
|
37
|
Zhou J, Li L, Li X, Yu Q, Cui S, Shu K,
Liu J, Liu J, Ding D and Du T: Efficacy analysis of a novel
thermochemotherapy scheme with pirarubicin for intermediate- and
high-risk nonmuscle-invasive bladder cancer: A single-institution
nonrandomized concurrent controlled trial. Int J Hyperthermia.
36:868–875. 2019. View Article : Google Scholar
|
|
38
|
Favoulet P, Benoit L, Osmak L, Polycarpe
E, Esquis P, Duvillard C, Guiu B, Rat P, Favre JP and Chauffert B:
Prevention of peritoneal carcinomatosis from colon cancer cell
seeding using a pirarubicin solution in rats and nude mice. World J
Surg. 28:451–456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oei AL, Vriend LE, Crezee J, Franken NA
and Krawczyk PM: Effects of hyperthermia on DNA repair pathways:
One treatment to inhibit them all. Radiat Oncol. 10:1652015.
View Article : Google Scholar
|
|
40
|
Lammers RJ, Witjes JA, Inman BA,
Leibovitch I, Laufer M, Nativ O and Colombo R: The role of a
combined regimen with intravesical chemotherapy and hyperthermia in
the management of non-muscle-invasive bladder cancer: A systematic
review. Eur Urol. 60:81–93. 2011. View Article : Google Scholar
|
|
41
|
Melgarejo Segura MT, Morales Martínez A,
Yáñez Castillo Y, Arrabal Polo MÁ, Gómez Lechuga P, Pareja Vílchez
M and Arrabal Martín M: Conductive hyperthermic chemotherapy versus
electromotive drug administration of mitomycin C as intravesical
adjuvant treatment of patients with intermediate or high-risk
non-muscle invasive bladder cancer. Urol Oncol. 41:109.e1–109.e8.
2023. View Article : Google Scholar
|
|
42
|
Guerrero-Ramos F, González-Padilla DA,
González-Díaz A, de la Rosa-Kehrmann F, Rodríguez-Antolín A, Inman
BA and Villacampa-Aubá F: Recirculating hyperthermic intravesical
chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk
non-muscle-invasive bladder cancer: Results of the HIVEC-HR
randomized clinical trial. World J Urol. 40:999–1004. 2022.
View Article : Google Scholar
|
|
43
|
Conroy S, Pang K, Jubber I, Hussain SA,
Rosario DJ, Cumberbatch MG, Catto JWF and Noon AP: Hyperthermic
intravesical chemotherapy with mitomycin-C for the treatment of
high-risk non-muscle-invasive bladder cancer patients. BJUI
Compass. 4:314–321. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Plata A, Guerrero-Ramos F, Garcia C,
González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM,
Díaz-Goizueta FJ, Del Álamo JF, Gonzalo V, Montero J, et al:
Long-Term experience with hyperthermic chemotherapy (HIVEC) Using
Mitomycin-C in Patients with non-muscle invasive bladder cancer in
Spain. J Clin Med. 10:51052021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Morales A, Eidinger D and Bruce AW:
Intracavitary bacillus calmette-guerin in the treatment of
superficial bladder tumors. J Urol. 116:180–182. 1976. View Article : Google Scholar
|
|
46
|
Kamat AM, Flaig TW, Grossman HB, Konety B,
Lamm D, O'Donnell MA, Uchio E, Efstathiou JA and Taylor JA III:
Consensus statement on best practice management regarding the use
of intravesical immunotherapy with BCG for bladder cancer. Nat Rev
Urol. 12:225–235. 2015. View Article : Google Scholar
|
|
47
|
Jiang S and Redelman-Sidi G: BCG in
bladder cancer immunotherapy. Cancers (Basel). 14:30732022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kamat AM, Briggman J, Urbauer DL, Svatek
R, Nogueras González GM, Anderson R, Grossman HB, Prat F and Dinney
CP: Cytokine panel for response to intravesical therapy (CyPRIT):
Nomogram of changes in urinary cytokine levels predicts patient
response to bacillus calmette-guérin. Eur Urol. 69:197–200. 2016.
View Article : Google Scholar
|
|
49
|
Han J, Gu X, Li Y and Wu Q: Mechanisms of
BCG in the treatment of bladder cancer-current understanding and
the prospect. Biomed Pharmacother. 129:1103932020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lamm DL: Bacillus calmette-guerin
immunotherapy for bladder cancer. J Urol. 134:40–47. 1985.
View Article : Google Scholar
|
|
51
|
Heckler M, Ali LR, Clancy-Thompson E,
Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K,
Peters V, et al: Inhibition of CDK4/6 Promotes CD8 T-cell memory
formation. Cancer Discov. 11:2564–2581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chung R, McKiernan J, Arpaia N, Marabelle
A and Rouanne M: Neo-Adjuvant immunotherapies: Bladder cancer as a
platform for drug development targeting mucosal immunity. Eur J
Cancer. 187:58–64. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Leko V, McDuffie LA, Zheng Z, Gartner JJ,
Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA and Lu YC:
Identification of neoantigen-reactive tumor-infiltrating
lymphocytes in primary bladder cancer. J Immunol. 202:3458–3467.
2019. View Article : Google Scholar
|
|
54
|
Mohamed F, Marchettini P, Stuart OA, Urano
M and Sugarbaker PH: Thermal enhancement of new chemotherapeutic
agents at moderate hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
View Article : Google Scholar
|
|
55
|
Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks
JJ, McConkey DJ, Gelfond JA, Curiel TJ and Svatek RS: γδ T cells
support antigen-specific αβ T cell-mediated antitumor responses
during BCG treatment for bladder cancer. Cancer Immunol Res.
9:1491–1503. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen F, Zhang G, Iwamoto Y and See WA: BCG
directly induces cell cycle arrest in human transitional carcinoma
cell lines as a consequence of integrin cross-linking. BMC Urol.
5:82005. View Article : Google Scholar
|
|
57
|
Yu DS, Wu CL, Ping SY, Keng C and Shen KH:
Bacille Calmette-Guerin can induce cellular apoptosis of urothelial
cancer directly through toll-like receptor 7 activation. Kaohsiung
J Med Sci. 31:391–397. 2015. View Article : Google Scholar
|
|
58
|
Sandes E, Lodillinsky C, Cwirenbaum R,
Argüelles C, Casabé A and Eiján AM: Cathepsin B is involved in the
apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in
transitional cancer cell lines. Int J Mol Med. 20:823–828.
2007.PubMed/NCBI
|
|
59
|
Sylvester RJ, Brausi MA, Kirkels WJ,
Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van
de Beek C, Gorlia T, et al: Long-Term efficacy results of EORTC
genito-urinary group randomized phase 3 study 30911 comparing
intravesical instillations of epirubicin, bacillus calmette-guérin,
and bacillus calmette-guérin plus isoniazid in patients with
intermediate- and high-risk stage Ta T1 urothelial carcinoma of the
bladder. Eur Urol. 57:766–773. 2010. View Article : Google Scholar
|
|
60
|
Pook SH, Rahmat JNB, Esuvaranathan K and
Mahendran R: Internalization of Mycobacterium bovis, Bacillus
Calmette Guerin, by bladder cancer cells is cytotoxic. Oncol Rep.
18:1315–1320. 2007.PubMed/NCBI
|
|
61
|
Zhang G, Chen F, Cao Y, Amos JV, Shah G
and See WA: HMGB1 release by urothelial carcinoma cells in response
to bacillus calmette-guérin functions as a paracrine factor to
potentiate the direct cellular effects of bacillus calmette-guérin.
J Urol. 190:1076–1082. 2013. View Article : Google Scholar
|
|
62
|
Kawai K, Miyazaki J, Joraku A, Nishiyama H
and Akaza H: Bacillus Calmette-Guerin (BCG) immunotherapy for
bladder cancer: Current understanding and perspectives on
engineered BCG vaccine. Cancer Sci. 104:22–27. 2013. View Article : Google Scholar
|
|
63
|
Muto S, Lu Y, Ide H, Yamaguchi R, Saito K,
Kitamura K, Noma Y, Koyasu H, Hirano H, Ashizawa T, et al: The use
of urine mycobacterium tuberculosis complex polymerase chain
reaction as a predictive factor for recurrence and progression
after intravesical bacillus calmette-guérin therapy in patients
with non-muscle-invasive bladder cancer. Eur Urol Open Sci.
27:10–18. 2021. View Article : Google Scholar
|
|
64
|
Waked R, Choucair J, Chehata N, Haddad E
and Saliba G: Intravesical Bacillus Calmette-Guérin (BCG)
treatment's severe complications: A single institution review of
incidence, presentation and treatment outcome. J Clin Tuberc
Mycobact Dis. 19:1001492020.
|
|
65
|
Belldegrun AS, Franklin JR, O'Donnell MA,
Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL and Williams RD:
Superficial bladder cancer: The role of interferon-alpha. J Urol.
159:1793–1801. 1998. View Article : Google Scholar
|
|
66
|
Samuel CE: Antiviral Actions of
Interferons. Clin Microbiol Rev. 14:778–809. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Boorjian SA, Alemozaffar M, Konety BR,
Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS,
Lerner SP, Busby JE, et al: Intravesical nadofaragene firadenovec
gene therapy for BCG-unresponsive non-muscle-invasive bladder
cancer: A single-arm, open-label, repeat-dose clinical trial.
Lancet Oncol. 22:107–117. 2021. View Article : Google Scholar
|
|
68
|
Öhlund D, Elyada E and Tuveson D:
Fibroblast heterogeneity in the cancer wound. J Exp Med.
211:1503–1523. 2014. View Article : Google Scholar
|
|
69
|
Hou R, Kong X, Yang B, Xie Y and Chen G:
SLC14A1: A novel target for human urothelial cancer. Clin Transl
Oncol. 19:1438–1446. 2017. View Article : Google Scholar
|
|
70
|
Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G,
Yin J, Liang X and Liu Z: Interferon-dependent SLC14A1+
cancer-associated fibroblasts promote cancer stemness via WNT5A in
bladder cancer. Cancer Cell. 40:1550–1565.e7. 2022. View Article : Google Scholar
|
|
71
|
Lee A: Nadofaragene firadenovec: First
approval. Drugs. 83:353–357. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shepherd AR, Shepherd E and Brook NR:
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus
intravesical Bacillus Calmette-Guérin for treating
non-muscle-invasive bladder cancer. Cochrane Database Syst Rev.
3:CD0121122017.PubMed/NCBI
|
|
73
|
Pagès F, Lebel-Binay S, Vieillefond A,
Deneux L, Cambillau M, Soubrane O, Debré B, Tardy D, Lemonne JL,
Abastado JP, et al: Local immunostimulation induced by intravesical
administration of autologous interferon-gamma-activated macrophages
in patients with superficial bladder cancer. Clin Exp Immunol.
127:303–309. 2002. View Article : Google Scholar
|
|
74
|
Harris JR and Markl J: Keyhole limpet
hemocyanin (KLH): A biomedical review. Micron. 30:597–623. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dolashki A, Dolashka P, Stenzl A,
Stevanovic S, Aicher WK, Velkova L, Velikova R and Voelter W:
Antitumour activity of Helix hemocyanin against bladder carcinoma
permanent cell lines. Biotechnol Biotechnol Equip. 33:20–32. 2019.
View Article : Google Scholar
|
|
76
|
Lamm DL, DeHaven JI, Riggs DR and Ebert
RF: Immunotherapy of murine bladder cancer with keyhole limpet
hemocyanin (KLH). J Urol. 149:648–652. 1993. View Article : Google Scholar
|
|
77
|
Colotta F, Rambaldi A, Colombo N, Tabacchi
L, Introna M and Mantovani A: Effect of a streptococcal preparation
(OK432) on natural killer activity of tumour-associated lymphoid
cells in human ovarian carcinoma and on lysis of fresh ovarian
tumour cells. Br J Cancer. 48:515–525. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yamaguchi Y, Ohshita A, Kawabuchi Y,
Hihara J, Miyahara E, Noma K and Toge T: Locoregional immunotherapy
of malignant ascites from gastric cancer using DTH-oriented doses
of the streptococcal preparation OK-432: Treatment of Th1
dysfunction in the ascites microenvironment. Int J Oncol.
24:959–966. 2004.
|
|
79
|
Huang H, Kong D, Liu Y, Cui Q, Wang K,
Zhang D, Wang J, Zhai M, Yan J, Zhang C and Wu G: Sapylin promotes
wound healing in mouse skin flaps. Am J Transl Res. 9:3017–3026.
2017.PubMed/NCBI
|
|
80
|
Liu ZH, Zheng FF, Mao YL, Ye LF, Bian J,
Lai DH, Ye YL and Dai YP: Effects of programmed death-ligand 1
expression on OK-432 immunotherapy following transurethral
resection in non-muscle invasive bladder cancer. Oncol Lett.
13:4818–4824. 2017. View Article : Google Scholar
|
|
81
|
Fujita K: The role of adjunctive
immunotherapy in superficial bladder cancer. Cancer. 59:2027–2030.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Speth PA, van Hoesel QG and Haanen C:
Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet.
15:15–31. 1988. View Article : Google Scholar
|
|
83
|
Badalament RA and Farah RN: Treatment of
superficial bladder cancer with intravesical chemotherapy. Semin
Surg Oncol. 13:335–341. 1997. View Article : Google Scholar
|
|
84
|
Zincke H, Utz DC, Taylor WF, Myers RP and
Leary FJ: Influence of thiotepa and doxorubicin instillation at
time of transurethral surgical treatment of bladder cancer on tumor
recurrence: A prospective, randomized, double-blind, controlled
trial. J Urol. 129:505–509. 1983. View Article : Google Scholar
|
|
85
|
Kurth K, Tunn U, Ay R, Schröder FH,
Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M and Sylvester
R: Adjuvant chemotherapy for superficial transitional cell bladder
carcinoma: Long-term results of a European Organization for
Research and Treatment of Cancer randomized trial comparing
doxorubicin, ethoglucid and transurethral resection alone. J Urol.
158:378–384. 1997. View Article : Google Scholar
|
|
86
|
Yee SB and Pritsos CA: Reductive
activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse
mammary carcinoma tumors. Chem Biol Interact. 104:87–101. 1997.
View Article : Google Scholar
|
|
87
|
Niijima T, Koiso K and Akaza H: Randomized
clinical trial on chemoprophylaxis of recurrence in cases of
superficial bladder cancer. Cancer Chemother Pharmacol. 11
(Suppl):S79–S82. 1983. View Article : Google Scholar
|
|
88
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang JY, Wei W, Lan YL, Liu JQ, Wang HB
and Li S: Role of bladder hydrodistention and intravesical sodium
hyaluronate in the treatment of interstitial cystitis. Urol J.
12:2417–2421. 2015.PubMed/NCBI
|
|
90
|
Batts CN: Adjuvant intravesical therapy
for superficial bladder cancer. Ann Pharmacother. 26:1270–1276.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xue R, Zhao C, Chen D, Wang P, Xing W,
Zeng W and Li Q: Potential influence of anaesthesia techniques on
the recurrence and progression after resection of
non-muscle-invasive bladder cancer: A propensity score-matched
analysis. BMC Anesthesiol. 22:2632022. View Article : Google Scholar
|
|
92
|
Teng X, Liu Y, Wang L and Wang G:
Lidocaine exerts anticancer activity in bladder cancer by targeting
isoprenylcysteine carboxylmethyltransferase (ICMT). Transl Androl
Urol. 10:4219–4230. 2021. View Article : Google Scholar
|
|
93
|
Yang X, Zhao L, Li M, Yan L, Zhang S, Mi
Z, Ren L and Xu J: Lidocaine enhances the effects of
chemotherapeutic drugs against bladder cancer. Sci Rep. 8:5982018.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Böhle A, Leyh H, Frei C, Kühn M, Tschada
R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, et
al: Single postoperative instillation of gemcitabine in patients
with non-muscle-invasive transitional cell carcinoma of the
bladder: A randomised, double-blind, placebo-controlled phase III
multicentre study. Eur Urol. 56:495–503. 2009. View Article : Google Scholar
|
|
95
|
Chen SY, Du LD and Zhang YH: Pilot study
of intravesical instillation of two new generation anthracycline
antibiotics in prevention of superficial bladder cancer recurrence.
Chin Med J (Engl). 123:3422–3426. 2010.PubMed/NCBI
|
|
96
|
Cozzi PJ, Bajorin DF, Tong W, Nguyen H,
Scott J, Heston WD and Dalbagni G: Toxicology and pharmacokinetics
of intravesical gemcitabine: A preclinical study in dogs. Clin
Cancer Res. 5:2629–2637. 1999.PubMed/NCBI
|
|
97
|
Beaussier M, Delbos A, Maurice-Szamburski
A, Ecoffey C and Mercadal L: Perioperative use of intravenous
lidocaine. Drugs. 78:1229–1246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Pederzoli F, Bandini M, Raggi D, Marandino
L, Basile G, Alfano M, Colombo R, Salonia A, Briganti A, Gallina A,
et al: Is there a detrimental effect of antibiotic therapy in
patients with muscle-invasive bladder cancer treated with
neoadjuvant pembrolizumab? Eur Urol. 80:319–322. 2021. View Article : Google Scholar
|
